Binding of factor VIII to von Willebrand factor is enabled by cleavage of the von Willebrand factor propeptide and enhanced by formation of disulfide-linked multimers

Blood

Volumn 92, Issue 2, 1998, Pages 529-538

  Bendetowicz, Ana Victoria ^a,e   Morris, Jill A ^b   Wise, Robert J ^c   Gilbert, Gary E ^d   Kaufman, Randal J ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; PROTEIN PRECURSOR; VON WILLEBRAND FACTOR;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; BLOOD CLOTTING; DISULFIDE BOND; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN MODIFICATION;

EID: 0032528532     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.2.529.414k31_529_538     Document Type: Article

References (48)

1. van Dieijen G, Tans G, Rosing J, Hemker H: The role of phospholipid and factor Villa in the activation of bovine factor X. J Biol Chem 256:3433,1981
2. Patek A, Taylor F: Hemophilia. II. Some properties of a substance obtained from normal human plasma effective in accelerating the clotting of hémophilie blood. J Clin Invest 16:113,1937
3. Gilbert GE, Drinkwater D, Barter S, Clouse SB: Specificity of phosphatidylserine-containing membrane binding sites for factor VIII: Studies with model membranes supported by glass microspheres (Lipospheres). J Biol Chem 267:15861,1992
4. Kaufman RJ, Wasley LC, Dorner AJ: Synthesis, processing and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem 263:6352,1988
5. Kaufman RJ, Wasley LC, Davies MV, Wise RJ, Israel DI, Dorner AJ: The effect of von Willlebrand factor co-expression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells. Mol Cell Biol 9:1233,1989
6. Rick ME, Esmon NL, Krized DM: Factor IXa and von Willebrand factor modify the inactivation of factor VIII by activated protein C. J Lab Clin Med 115:415, 1990
7. Sadler JE, Shelton-Inloes BB, Sorace JM, Marian JM, Titani K, Davie EW: Cloning and characterization of two cDNAs coding for human von Willebrand factor. Proc Natl Acad Sei USA 82:6394,1985
8. Verweij CL, Diergaarde PMH, Pannekoek H: Full-length von Willebrand factor (vWF) cDNA encodes a highly repetitive protein, considerably larger than the mature vWF subunit. EMBO J 5:1839,1986
9. Bonthron DT, Handin RI, Kaufman RJ, Wasley LC, Orr EC, Mitsock LM, Ewenstein B, Loscalzo J, Ginsburg D, Orkin SH: Structure of pre-pro von Willebrand factor and its expression in heterologous cells. Nature 324:270,1986
10. Hoyer LW, Shainoff JR: Factor Vlll-related protein circulates in normal human plasma as high molecular weight multimers. Blood 55:1056,1980
11. Ruggeri ZM, Zimmerman TS: The complex multimeric composition of factor Vlll/von Willebrand factor. Blood 57:1140,1981
12. Marti T, Rosselet SJ, Titani R, Walsh KA: Identification of disulfide-bridged structures within human von Willebrand factor. Biochemistry 26:8099, 1987
13. Wagner DD, Marder VJ: Biosynthesis of von Willebrand protein by human endothelial cells: Processing steps and their intracellular localization. J Cell Biol 99:2123,1984
14. Sadler JE: von Willebrand factor. J Biol Chem 266:22777, 1991
15. Wise RJ, Pittman DD, Handin RI, Kaufman RJ, Orkin SH: The propeptide of vWF is required for the assembly of von Willebrand subunits into disulfide-linked multimers. Cell 52:229,1988
16. Verweij CL, Hart M, Pannekoek H: Expression of a variant von Willebrand factor vWF cDNA in heterologous cells: Requirement of the propolypeptide in vWF multimer assembly. EMBO J 6:2885,1987
17. Koedam JA: Interaction Between Factor VIII and vWF. PhD Thesis, University of Utrecht, Utrecht, The Netherlands, 1989
18. Foster PA, Fulcher CA, Marti T, Titani K, Zimmerman TS: A major factor VIII binding domain resides within the ammo-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem 262:8443, 1987
19. Bahou WF, Ginsburg D, Sikkink R, Litwiller R, Pass DN: A monoclonal antibody to von Willebrand factor (vWF) inhibits factor VIII binding. J Clin Invest 84:56,1989
20. Takahashi Y, Kalafatis M, Girma J-P, Sewerin K, Andersson L-O, Meyer D: Localization of factor VIII binding domain on a 34 kilodalton fragment of the N-terminal portion of von Willebrand factor. Blood 70:1987,1987
21. Vischer UM, Wagner DD: von Willebrand factor proteolytic processing and multimerization precede the formation of Weibel-Palade bodies. Blood 83:3536,1994
22. Lynch DC, Williams R, Zimmerman TS, Kirby EP, Livingston DM: Biosynthesis of the subunits of factor VIIIR by bovine aortic endothelial cells. Proc Natl Acad Sei USA 80:2738,1983
23. Wise RJ, Barr PJ, Wong PA, Kiefer MC, Brake AJ, Kaufman RJ: Expression of a human proprotein processing enzyme: Correct cleavage of the von Willebrand factor precursor at a paired basic amino acid site. Proc Natl Acad Sei USA 87:9378,1990
24. Van der Ven WJM, Voorberg J, Fontijn R, Pannekoek H, Van den Ouweland AMW, Van Duynhoven HLF, Roebroek AJM, Siezen RJ: Furin is a subtilisin-like proprotein processing enzyme in higher eukaryotes. Mol Biol Rep 14:15,1990
25. Tuddenham E, Lane R, Rotblat F, Johnson A, Snape T, Middleton S, Kemoff P: Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human hemophilia A and von Willebrand's disease. Br J Haematol 52:259,1982
26. Over J, Sixma J, Bruine M, Trieschnigg M, Vlooswijk R, Beeser-Visser N, Bouma B: Survival of '^iodine-labeled factor VIII in normals and patients with classic hemophilia. J Clin Invest 62:223,1978
27. Weiss H, Sussman I, Hoyer L: Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest 60,1977
28. Mannucci PM, Tenconi PA, Castman G, Rodegheiro F: Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease. A cross-over randomized trial. Blood 79:3130,1992
29. Lollar P, Parker C: Stoichiometry of the porcine factor VIII-von Willebrand factor association. J Biol Chem 262:17572,1987
30. Zucker MB, Soberano ME, Johnson AJ, Fulton AJ, Kowalski S: The in vitro association of antihemophilic factor and von Willebrand factor. Thromb Haemost 49:37,1983
31. Hamer R, Koedam J, Beeser-Visser N, Bertina R, Van Mourik J, Sixma JJ: Factor VIII binds to von Willebrand factor via its A/r-80,000 light chain. Eur J Biochem 166:37,1987
32. Leyte A, Verbeet M, Brodniewicz-Proba T, van Mourik J, Mertens K: The interaction between human blood-coagulation factor VIII and von Willebrand factor: Characterization of a high-affinity binding site on factor VIII. Biochem J 257:679,1989
33. Nesheim ME, Pittman DD, Giles AR, Pass DN, Wang J, Slonosky D, Kaufman RJ: The effect of plasma von Willebrand factor on the binding of human factor VIII to thrombin-activated human platelets. J Biol Chem 266:17815,1991
34. Wise RJ, Domer AD, Krane M, Pittman DD, Kaufman RJ: The role of von Willebrand factor multimerization and propeptide cleavage in the binding and stabilization of factor VIII. J Biol Chem 266:21948, 1991
35. Leyte A, Voorberg J, van Schijndel H, Duim B, Pannekoek H, van Mourik J: The pro-polypeptide of von Willebrand factor is required for the formation of a functional factor VIII-binding site on mature von Willebrand factor. Biochem J 274:257,1991
36. Pittman DD, Millenson M, Marquette K, Bauer KA, Kaufman RJ: A2 domain of human recombinant-derived factor VIII is required for procoagulant activity but not for thrombin cleavage. Blood 79:389, 1992
37. Bardelle C, Furie B, Furie BC, Gilbert GE: Membrane binding kinetics of factor VIII indicate a complex binding process. J Biol Chem 268:8815,1993
38. Harlow E, Lane D: Antibodies: A Laboratory Manual. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1988
39. Rehemetulla A, Kaufman RJ: Preferred sequence requirements for cleavage of pro-vWF by propeptide processing enzymes. Blood 9:2349,1992
40. Kaufman RJ: Vectors used for expression in mammalian cells. Methods Enzymol 185:487,1990
41. Faassem AE, Schräger JA, Klein DJ, Oegema TR, Couchman JR, McCarthy JB : A cell surface chondroitin sulfate proteoglycan, immunologically related to CD44, is involved in type I collagen-mediated melanoma cell motility and invasion. J Cell Biol 116:521,1992
42. Towbin H, Staehelin T, Gordon J: Electrophorestic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sei USA 76:4350,1979
43. Vlot AJ, Koppelman SJ, van den Berg MH, Bouma BN, Sixma JJ: The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor. Blood 85:3150,1995
44. Mayadas TN, Wagner DD: Vicinal cysteines in the prosequence play a role in von Willebrand factor multimer assembly. Proc Natl Acad Sei USA 89:3531,1992
45. Saenko EL, Scandella D: The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von Willebrand factor. J Biol Chem 272:18007,1997
46. Shima M, Scandella D, Yoshioka A, Nakai H, Tanaka I, Kamisue S, Terada S, Fukui H: A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost 69:240,1993
47. Saenko EL, Shima M, Rajalakshmi KJ, Scandella D: A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem 269:11601,1994
48. Koppelman SJ, van Hoeij M, VmkT, Lankhof H, Schiphorts ME, Damas C, Vlot AJ, Wise RJ, Bouma BN, Sixma JJ: Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C. Blood 87:2292,1996